In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Joslin Diabetes Center

www.joslin.harvard.edu

Latest From Joslin Diabetes Center

Deals Shaping The Medical Industry, March 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2016.

BioPharmaceutical Medical Device

Deals Shaping the Medical Industry, February 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2016.

BioPharmaceutical Medical Device

MedImmune Looking For Multi-Purpose Biologics For Metabolic Diseases

Coming in from University of Chicago, Christopher Rhodes is heading up cardiovascular and metabolic research, with a goal to find biologic candidates that act early in the cascade of events across a range of disease issues.

BioPharmaceutical Research and Development Strategies

Biopharma Quarterly Dealmaking Statistics, Q1 2015

Biopharma financing reached $15.1 billion, with record-breaking FOPO dollar volume making up close to $10 billion of the total; AbbVie topped the $66.5 billion M&A activity with its $20 billion buy of Pharmacyclics; and gastroenterology was one of the most highly partnered therapeutic areas.

BioPharmaceutical Deals
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register